<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">Essential thrombocythemia</z:e> (ET) is a clonal disorder of the myeloid stem cell that causes pathologic expansion of the megakaryocytic elements in the bone marrow, with a persistent increase in the platelet count </plain></SENT>
<SENT sid="1" pm="."><plain>In order to avoid the mutagenic effects of radioactive phosphorous and <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, various European clinicians use pipobroman rather than <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> as single chemotherapeutic treatment, since it is simple and well tolerated and does not lead to hematological complications or the risk of visceral <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we describe a 63-year-old ET patient who showed myelodysplastic transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) of the <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> after about eight years of therapy with pipobroman at variable dosages </plain></SENT>
</text></document>